TICKERNERD
Menu
ZURAZURAHealthcare · Biotechnology

ZURA Stock Forecast: Zura Bio Ltd. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$5.57
−1.07% on the day

The 7 Wall Street analysts covering Zura Bio Ltd. hold a median 12-month price target of $18 — +223.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$533.8M
Ticker Nerd rank
32 / 100
Median analyst target
$18
Analysts covering
7
Total return, dividends reinvested
1W
−6.6%
1M
+10.1%
YTD
+6.3%
1Y
+223.8%
From 52W high
−20.9%
From 52W low
+235.5%
$1.66
$7.04
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZURA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zura Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Volatility
67
Size
53
Accruals
41
Value
41
Quality
36
Issuance
31
Revisions
29
Growth
28

Momentum (95): The shares have been drifting up relative to others.

Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ZURA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZURA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26ZURAHigh $26Median $18Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $11Median $18High $26

The green dot is the last close — the median target sits +223.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026GuggenheimMaintainsBuy$15 → $20
12 Aug 2026WedbushMaintainsOutperform$15 → $22
8 July 2026William BlairInitiatesOutperform—
8 July 2026William BlairInitiatesOutperform—
1 July 2026WedbushReiteratesOutperform—
1 July 2026WedbushReiteratesOutperform$15
23 Mar 2026Chardan CapitalMaintainsBuy—
20 Mar 2026OppenheimerMaintainsOutperform—
9 Feb 2026WedbushInitiatesOutperform—
14 Nov 2025Chardan CapitalMaintainsBuy—
13 Nov 2025Clear StreetInitiatesBuy—
30 Sept 2025Chardan CapitalMaintainsBuy—
19 Aug 2025HC Wainwright & Co.MaintainsNeutral—
15 Aug 2025Chardan CapitalMaintainsBuy—
15 Aug 2025OppenheimerMaintainsOutperform—
9 May 2025OppenheimerMaintainsOutperform—
3 Apr 2025HC Wainwright & Co.MaintainsNeutral—
26 Mar 2025Chardan CapitalMaintainsBuy—
26 Mar 2025GuggenheimReiteratesBuy—
26 Mar 2025OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZURA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ZURA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Zura Bio Ltd. (ZURA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.9×

Cheaper than 62% of US stocks

Price / sales
—
Price / book
2.7×

Cheaper than 38% of US stocks

EV / EBITDA
−3.5×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−51.0%

Higher than 21% of US stocks

Return on assets
−31.2%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ZURA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZURAZura Bio Ltd.$533.8M
32
OVIDOvid Therapeutics, Inc.$528.2M
67
EVMNEvommune, Inc.$527.7M
10
PRLDPrelude Therapeutics, Inc.$524.7M
96
CCCCC4 Therapeutics, Inc.$521.6M
68
MPLTMapLight Therapeutics, Inc.$512.8M
7
CTNMContineum Therapeutics, Inc.$550.0M
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zura Bio Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZURA news & analysis

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Business Wire · 11 Aug 2026positive

Zura Bio Limited reported its financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. Management highlighted strong execution across the company's tibulizumab programs, noting that enrollment is now complete.

Why it matters — ZURA watchers would care because the report confirms progress on the company's lead tibulizumab programs and provides a snapshot of its financial standing for the quarter.

FAQ

Frequently asked questions about ZURA stock

What is the ZURA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Zura Bio Ltd. have a median 12-month price target of $18, with estimates ranging from $11 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZURA stock a buy right now?

Of the 7 analysts covering Zura Bio Ltd., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zura Bio Ltd. 32 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZURA?

As at 15 Aug 2026, Zura Bio Ltd. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will ZURA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +223.2% from the last close, and Ticker Nerd's factor model ranks Zura Bio Ltd. 32 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZURA stock forecast for 2030?

No analyst covering Zura Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $26 over the next 12 months.

How has ZURA stock performed over the past year?

Zura Bio Ltd. returned +223.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zura Bio Ltd. do?

Zura Bio Ltd. is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases.

What is the latest news on ZURA?

The most recent item we track (Business Wire, 11 Aug 2026): "Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates". Zura Bio Limited reported its financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. Management highlighted strong execution across the company's tibulizumab programs, noting that enrollment is now complete.

Company

About Zura Bio Ltd.

Zura Bio Ltd. is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company focuses on advancing a pipeline that includes tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF, currently in Phase 2 trials such as TibuSHIELD for moderate to severe hidradenitis suppurativa and TibuSURE for systemic sclerosis. Additional assets include crebankitug (ZB-168) and torudokimab (ZB-880), which have completed Phase 1/Ib studies and are Phase 2 ready, targeting a portfolio of therapeutic indications to demonstrate efficacy, safety, and dosing convenience. Zura Bio Ltd. employs a dual antagonism strategy to address the heterogeneity of autoimmune diseases by simultaneously targeting multiple pathways, potentially offering improved treatment outcomes for underserved patients. Led by biotechnology entrepreneurs and pharmaceutical professionals, the company operates in the immunology sector, contributing to the development of innovative medicines for serious immune system disorders.

CEO Dr. Sandeep Chidambar Kulkarni M.D. · 40 employees · United States · https://zurabio.com